Biotechnology Index

Biotechnology Index

A group of NASDAQ-listed companies designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The NASDAQ Biotechnology Index (BI) is calculated under a modified capitalisation-weighted methodology.

The BI currently includes Affymetrix, Amgen, Applera Corp-Celera Genomics Group, Biogen, Cephalon, Chiron, COR Therapeutics, Genzyme Corporation, Genentech Inc, Gilead Sciences, Human Genome Sciences, IIDEC Pharmaceuticals, Immunex Corporation, Medimmune, Millennium Pharmaceuticals, Protein Design Labs and Vertex Pharmaceuticals.
Mentioned in ?
References in periodicals archive ?
The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) is up about 10%.
BIOTECH STOCKS NEAR 2019 LOWS: The iShares Nasdaq Biotechnology Index, an ETF that tracks the stocks of biotech group, is trading relatively unchanged since early January of 2019.
Cooley is counsel to more than 1400 public and private life sciences companies across the globe and counsel to more than 50% of the companies on the NASDAQ Biotechnology Index.
The Nasdaq Biotechnology Index, often used as a barometer for investor sentiment about drug prices, was up 0.1 percent after rising as much as 0.5 percent earlier.
The SandP healthcare index ended 1.47 percent higher, while the Nasdaq Biotechnology index rallied 2.68 percent.
M2 PHARMA-December 19, 2017-GlycoMimetics to Join NASDAQ Biotechnology Index
The Nasdaq Biotechnology Index is up 29% since the start of the year, and outpacing other indices.
Anacor gave one of the biggest boosts to the Nasdaq Biotechnology index, which gained some 3 percent.
Even with the recent downturn, the NASDAQ Biotechnology Index (IBB) has increased 250% in the past five years.
UBIO seeks to provide 3x and ZBIO seeks to provide -3x the daily performance of the Nasdaq Biotechnology Index, before fees and expenses.
The Nasdaq Biotechnology Index slipped 2.2 percent, paring its best quarterly gain since 2013.
After a year of remarkable gains--accentuated by a near-record number of initial public offerings (IPOs) and 61 percent rise in the NASDAQ Biotechnology Index (the gain is more than double the S&P 500's 26 percent growth in 2013)--biotech stocks have significantly lost their luster.

Full browser ?